---
title: "Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans"
description: "Polaryx Therapeutics (NASDAQ: PLYX) shares surged 46.06% to $3.52 following the selection of a research organization for its SOTERIA Phase 2 trial. This trial will evaluate the safety and efficacy of "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276143893.md"
published_at: "2026-02-17T15:26:30.000Z"
---

# Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans

> Polaryx Therapeutics (NASDAQ: PLYX) shares surged 46.06% to $3.52 following the selection of a research organization for its SOTERIA Phase 2 trial. This trial will evaluate the safety and efficacy of PLX-200 for lysosomal storage disorders, with plans to initiate in the first half of 2026. The FDA granted a safe to proceed letter in October 2025, and the trial aims to gather data that could lead to conditional marketing authorization if successful.

**Polaryx Therapeutics Inc.** (NASDAQ:PLYX) shares are up on Tuesday as the company has made significant strides in advancing its clinical programs.

The positive movement follows the announcement that Polaryx has selected a contract research organization for its SOTERIA Phase 2 basket trial, which aims to evaluate its lead candidate, PLX-200, across multiple lysosomal storage disorders.

The SOTERIA trial represents a flexible and resource-efficient mechanism for the clinical development of PLX-200.

Polaryx’s selection of a leading contract research organization marks a pivotal milestone as it prepares to initiate the SOTERIA trial in the first half of 2026. The trial is designed to assess the safety, tolerability, and clinical activity of PLX-200 across four different lysosomal storage disorders, with the company having received a safe to proceed letter from the FDA in October 2025.

The SOTERIA trial will incorporate analyses comparing natural history data as a control arm to the treated arm of PLX-200, which is an orally available compound derived from gemfibrozil. This trial is expected to gather crucial data that will inform the future clinical development pathway for PLX-200, potentially leading to conditional marketing authorization if compelling clinical activity is demonstrated.

**PLYX Price Action:** Polaryx Therapeutics shares were up 46.06% at $3.52 at the time of publication on Tuesday. The stock is trading near its 52-week low of $2.20, according to Benzinga Pro data.

*Photo: jittawit21/Shutterstock*

### Related Stocks

- [PLYX.US - Polaryx Therapeutics](https://longbridge.com/en/quote/PLYX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股盘中速递：Polaryx Therapeutics 跌 17.73%，成交量放大，市场情绪波动引发关注 | Polaryx Therapeutics 跌 17.73%；艾伯维跌 0.20%，成交额达到 11.98 亿美元；安进跌 0.05%，成交额达到 5.92 亿美元；吉利德科学涨 2.21%，成交额达到 5.27 亿美元；福泰制药跌 1.23 | [Link](https://longbridge.com/en/news/275013912.md) |
| Polaryx Therapeutics 宣布启动 PLX-200 治疗 Krabbe 病的 SOTERIA 试验 | Polaryx Therapeutics Inc. 宣布启动 SOTERIA 试验，以评估 PLX-200，这是一种针对克拉贝病的疗法。在 WORLDSymposium™ 上展示的新临床前数据表明，PLX-200 中的活性成分吉非贝齐能够减 | [Link](https://longbridge.com/en/news/275466866.md) |
| 美股盘中速递：Polaryx Therapeutics 跌 31.25%，成交量激增，市场情绪波动引发关注 | Polaryx Therapeutics 跌 31.25%；艾伯维涨 1.46%，成交额达到 2.27 亿美元；吉利德科学涨 0.38%，成交额达到 2.18 亿美元；Roivant Sciences 涨 17.74%，成交额达到 2.03 | [Link](https://longbridge.com/en/news/275147087.md) |
| 12 只医疗保健股票在周二盘中交易中出现波动 | 在周二的盘中交易中，Polaryx Therapeutics (PLYX) 录得显著上涨，涨幅达到 80.9%，价格为 4.36 美元，市值为 1.14 亿美元。其他 notable 的涨幅股票包括 Baird Medical Invest | [Link](https://longbridge.com/en/news/276150613.md) |
| 12 只医疗保健股票在周二盘前交易时段出现波动 | 在周二的盘前交易中，Polaryx Therapeutics (PLYX) 大幅上涨 103.3%，达到 4.9 美元，而 Masimo (MASI) 上涨 34.14%，至 174.59 美元。其他上涨的公司包括 Compass Path | [Link](https://longbridge.com/en/news/276121189.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.